NanoAssemblr®
Product Suite
Comparison
Precision NanoSystems’ proprietary NanoAssemblr® Platform enables the rapid and controlled manufacture of nanomedicines.
Nanoparticle, Liposome, LNP

Discovery

The
NanoAssemblr®
Spark
Freedom to Discover
With Instant Microliter
Nanomedicine Formulations

Learn More
NanoAssemblr Spark
sample-recovery
Unmatched
Sample Recovery

Advanced microfluidics allows microliter formulation volumes with near complete sample recovery.

intuitive-operation
Intuitive Operation

Simply pipette starting materials into wells, push a button, and pipette completed formulations out.

rapid-production

Rapid Production

The Spark formulation process requires less than 5 seconds, allowing hundreds of formulations to be made in hours.

robust-process

Robust Process

Electronic control minimizes batch-to-batch and user variability.

workflow-integration
Workflow Integration

The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture.

scalable

Scalable

Shared microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development.

Preclinical

The
NanoAssemblr®
Benchtop
Develop Future Nanomedicines

Learn More
NanoAssemblr Benchtop
outstanding-reproducibility
Outstanding
Reproducibility

Computer control removes batch-to-batch and user variability

intuitive-operation

Intuitive Workflow

Advanced microfluidics are simplified with easy connections and visual software

controlled-assembly

Controlled Assembly

Tune particle size with precise control over fluid flow rates

versatile

Versatile

Formulate small molecules, peptides, and nucleic acids into lipid, polymer or hybrid nanoparticles, and more.

speedy

Speedy and Efficient

Formulation runs require less than a minute. 30 - 40 formulations can be completed in a day for rapid optimization.

scalable

Scalable

Easily scale between 1mL and 15mL formulations on the Benchtop. Optimized formulations can be transferred to advanced preclinical and clinical scale with the Blaze™ and 8x Scale-up systems.

The
NanoAssemblr®
Blaze
Advance Preclinical
Nanomedicine Programs


Learn More
NanoAssemblr Blaze

speedy

Speedy and Efficient

Formulation runs require less than a minute. 30 - 40 formulations can be completed in a day for rapid optimization.

Untitled-2

Easy Scaleup

Easy Scaleup of Formulations developed on the NanoAssemblr® Benchtop.

rapid-production

High capacity

Greater formulation capacity with the simplicity and efficiency of the NanoAssemblr Benchtop.

Untitled-3

Validation
of inline dilution

Validation of Inline Dilution up to 5L.

controlled-assembly

high range
of formulation

Formulation of 10 mL to 1L batches.

Untitled-4

Scalable upstream
and downstream

Scale-up development of upstream and downstream processes.

Manufacturing

Scale-Up Program
Continuous flow microfluidic platform designed for scale-up manufacturing of nanoparticles under cGMP conditions. The Scale-up system’s formulation results are in sync with NanoAssemblr Benchtop and Blaze-generated particles.

Learn More
Scale-Up System
Polymeric Nanoparticle
What is Nanomedicine?
Nanomedicines represent the next paradigm in drug innovation, and current research has demonstrated improved efficacy, reduced side effects and revolutionary new treatment modalities like gene therapy and targeted medicine.
Our technology is only the beginning
The NanoAssemblr™ Platform is a unique product offering that uses proprietary microfluidic mixers optimized for the manufacture of nanomedicines.

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Poster

July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr® Platform

Read More PDF

Publication - Abstract

April 26, 2018

Small Methods

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery

Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More

Publication - Abstract

November 01, 2018

Neuron

Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

Dejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., . . . Sheng, M.

Read More

Publication - Abstract

October 29, 2018

Nature Communications

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti & Dan Peer...

Read More
Resource Center
MENU
X